Pittet

Home

About

Mikael Pittet's Lab

My laboratory performs a research program on the host immune response in vivo with the main goal to offer valuable new ways to combat cancer. We use various modalities, including in vivo imaging, to study where, when and how immune cells are produced, traffic, and mediate regulatory or effector functions. The studies make use of both genetic mouse models, which allow manipulations and analyses of mechanisms and causality, and human patient material, to ensure that the results are anchored in clinical correlates. This dual approach gives opportunities for discovery of novel contributions of the immune response to tumor progression, new biomarkers useful for diagnosis and prognosis, and novel targets for therapeutic intervention. Dr. Pittet directs Cancer Immunology Program at CSB and collaborates with several immunology programs at Harvard Medical School, Massachusetts General Hospital and Massachusetts Institute of Technology.


In vivo imaging of immune cells at different scales. Imaging modalities include single photon emission computed tomography - X-ray computed tomography (SPECT-CT), fluorescence mediated tomography (FMT), microscopic fiber optics, and intravital multiphoton microscopy (IVM).

Recent Publications (more...)

Miller MA, Chandra R, Cuccarese MF, Pfirschke C, Engblom C, Stapleton S, Adhikary U, Kohler RH, Mohan JF, Pittet MJ, Weissleder R
Radiation therapy primes tumors for nanotherapeutic delivery via macrophage-mediated vascular bursts
Sci Transl Med. 2017;9(392):eaal0225 - PMID: 28566423
Arlauckas SP*, Garris CS*, Kohler RH, Kitaoka M, Cuccarese MF, Yang KS, Miller MA, Carlson JC, Freeman GJ, Anthony RM, Weissleder R, Pittet MJ
In vivo imaging reveals a tumor-associated macrophage–mediated resistance pathway in anti–PD-1 therapy
Sci Transl Med. 2017;9(389):eaal3604 - PMID: 28490665 - Cover
Pfirschke C, Siwicki M, Liao HW, Pittet MJ
Tumor Microenvironment: No Effector T Cells without Dendritic Cells.
Cancer Cell. 2017;31(5):614-615 - PMID: 28486102
Pucci F, Rickelt S, Newton AP, Garris C, Nunes E, Evavold C, Pfirschke C, Engblom C, Mino-Kenudson M, Hynes RO, Weissleder R, Pittet MJ
PF4 Promotes Platelet Production and Lung Cancer Growth.
Cell Rep. 2016;17(7):1764-1772 - PMID: 27829148 - PMCID: PMC5108525

Recent News (more...)

2017-09-11: "Uncovering Cancer" - the work of Pittet Lab is featured in Nature Medicine article.
2017-08-10: CSB has been named as one of the NCI Innovative Research in Cancer Nanotechnology (IRCNs). The IRCNs engage in directed, product-focused research that aims to translate cutting-edge science and technology into the next generation of diagnostic and therapeutic tools. These platforms serve as the core technologies for a wide array of specific applications that will ultimately benefit cancer patients.
2017-06-05: CSB work is profiled in MGH Research Institute spotlight "Mass General Researchers Investigate the ‘Big Eaters’ of the Immune System: #MacrophageMonday"
2017-05-12: Best of 2016: An article by Pfirschke and Engblom from the Pittet laboratory on how to improve cancer immunotherapy is listed in the 2016 edition of “Best of Immunity” as one of the ten most-accessed articles from the Journal. Immunity publishes papers that report the most important advances in immunology research.